Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by CANADA LIFE ASSURANCE Co

CANADA LIFE ASSURANCE Co trimmed its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 26.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 107,140 shares of the biopharmaceutical company's stock after selling 38,605 shares during the quarter. CANADA LIFE ASSURANCE Co owned 0.08% of Halozyme Therapeutics worth $5,121,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Heck Capital Advisors LLC purchased a new position in Halozyme Therapeutics in the fourth quarter valued at approximately $29,000. CBIZ Investment Advisory Services LLC acquired a new stake in shares of Halozyme Therapeutics in the fourth quarter worth $29,000. Smartleaf Asset Management LLC lifted its holdings in shares of Halozyme Therapeutics by 29.2% during the 4th quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company's stock valued at $42,000 after acquiring an additional 197 shares in the last quarter. Venturi Wealth Management LLC purchased a new stake in Halozyme Therapeutics during the 4th quarter worth $69,000. Finally, Parkside Financial Bank & Trust increased its holdings in Halozyme Therapeutics by 21.8% in the 4th quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company's stock valued at $86,000 after purchasing an additional 322 shares in the last quarter. Hedge funds and other institutional investors own 97.79% of the company's stock.

Halozyme Therapeutics Stock Up 2.1 %

Shares of HALO traded up $1.24 during midday trading on Friday, hitting $60.49. The company had a trading volume of 992,970 shares, compared to its average volume of 1,438,838. The stock has a market cap of $7.47 billion, a price-to-earnings ratio of 17.64, a PEG ratio of 0.42 and a beta of 1.32. The company's 50 day moving average price is $60.50 and its 200 day moving average price is $55.12. The company has a quick ratio of 9.15, a current ratio of 7.80 and a debt-to-equity ratio of 4.14. Halozyme Therapeutics, Inc. has a 52 week low of $37.97 and a 52 week high of $66.00.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last released its earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 EPS for the quarter, topping analysts' consensus estimates of $1.17 by $0.02. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. The company had revenue of $298.01 million for the quarter, compared to the consensus estimate of $285.74 million. On average, equities research analysts predict that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Wall Street Analyst Weigh In

HALO has been the topic of a number of recent research reports. JPMorgan Chase & Co. boosted their price objective on Halozyme Therapeutics from $55.00 to $58.00 and gave the stock a "neutral" rating in a research note on Monday, April 21st. Piper Sandler upped their price target on Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a "neutral" rating in a report on Friday, January 10th. Wells Fargo & Company lowered their price objective on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating for the company in a research report on Monday, January 13th. HC Wainwright reissued a "buy" rating and set a $72.00 target price on shares of Halozyme Therapeutics in a research report on Friday. Finally, Benchmark reaffirmed a "buy" rating and set a $75.00 price target on shares of Halozyme Therapeutics in a report on Thursday, February 20th. Four analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $62.89.

Insider Activity

In related news, Director Jeffrey William Henderson sold 5,000 shares of the firm's stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $56.30, for a total value of $281,500.00. Following the sale, the director now directly owns 38,611 shares in the company, valued at $2,173,799.30. This trade represents a 11.46 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Michael J. Labarre sold 1,697 shares of the business's stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $58.28, for a total value of $98,901.16. Following the transaction, the senior vice president now owns 173,756 shares of the company's stock, valued at $10,126,499.68. This trade represents a 0.97 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 22,200 shares of company stock valued at $1,286,568. 2.40% of the stock is currently owned by company insiders.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.